Conventional daily basal insulin, though a standard T2D treatment for patients failing oral agents or with severely elevated HbA1c, poses significant clinical challenges: high treatment burden, cost concerns, reduced flexibility, and reliance on others for administration (11). The gene discussed is INS; the disease is type 2 diabetes mellitus.